Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
about
Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
description
clinical trial
@en
klinisch onderzoek
@nl
name
Efficacy and Safety Study of C ...... Followed by an Extension Phase
@en
type
label
Efficacy and Safety Study of C ...... Followed by an Extension Phase
@en
prefLabel
Efficacy and Safety Study of C ...... Followed by an Extension Phase
@en
P1050
P1476
An Open-label, Efficacy and Sa ...... Approved and Marketed in Japan
@en
P17
P3098
NCT00991146
P580
2009-10-01T00:00:00Z
P582
2012-02-01T00:00:00Z